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Objective:  The  purpose  of  the  study  was  to  evaluate  the  clinical  effects  of  the  Shenzhu  TiaopiImpaired  glucose
granule (SZTP)  combined  with  a  lifestyle  intervention  in  patients  with  impaired  glucose  toler-tolerance  (IGT);
Spleen  deﬁciency  and
damp  overabundance
syndrome  (SDDOS);
ance (IGT),  who  also  had  a  spleen  deﬁciency  and  damp  overabundance  syndrome  (SDDOS).
Methods:  After  a  one-month  washout  period,  a  total  of  514  patients  were  randomly
assigned  to  the  control  (lifestyle  intervention)  and  experimental  (SZTP  plus  lifestyle  inter-
vention) groups,  with  257  patients  in  each  group.  Patients  in  the  control  group  received
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the  lifestyle  intervention  (diet  and  exercise)  for  12  months,  while  the  patients  in  the  experimental
group were  treated  with  SZTP  plus  the  lifestyle  intervention  for  12  months.  The  Traditional  Chi-
nese Medicinal  (TCM)  symptom  scores  were  observed  in  each  group  before  and  after  treatment;
the conversion  rates  from  IGT  to  diabetes  mellitus  (DM)  were  also  measured.
Results:  Following  12  months  of  treatment,  the  conversion  rate  from  IGT  to  DM  in  the  exper-
imental group  was  signiﬁcantly  lower  than  in  the  control  group  (8.52%  vs.  15.28%,  P  <  0.05).  A
signiﬁcantly  higher  number  of  patients  with  IGT  reverted  to  normal  blood  glucose  levels  in  the
experimental  group  than  in  the  control  group  (42.15%  vs.  32.87%,  P  <  0.05).  In  addition,  after
following  the  treatment  for  12  months,  the  TCM  symptoms  of  patients  in  the  experimental  group
were markedly  alleviated,  as  compared  to  the  control  group  (P  <  0.01).
Conclusion:  The  combination  of  SZTP  and  lifestyle  intervention  showed  a  reduction  in  the  con-
version from  IGT  to  DM,  and  an  increase  in  the  conversion  from  IGT  to  normal  blood  glucose
levels.
Shenzhu Tiaopi  granule
(SZTP);
Lifestyle
©  2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
BY-NC-SA license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Introduction
With  the  rapid  of  economic  development  around  the  world
resulting  in  reduced  levels  of  physical  activity  and  changes
in  dietary  habits,  the  incidence  and  prevalence  of  diabetes
Mellitus  (DM)  has  been  rising.  The  prevalence  of  diabetes  is
the  third  highest  among  non-infectious  diseases  in  China.1
Chinese  people  are  experiencing  steady  improvements  in  liv-
ing  standards,  changes  in  dietary  habits.  There  is  also  an
accelerated  pace  of  life,  as  well  as  an  increase  in  sedentary
lifestyle.  Also  the  population  of  China  is  rapidly  aging.  The
age-standardized  prevalence  of  DM  and  impaired  glucose
tolerance  (IGT)  (sometimes  referred  to  as  pre  diabetes  [PD])
during  the  PD  stage.2 Moreover,  the  prevalence  of  IGT  has
increased  faster  than  that  of  DM.  Thus,  IGT  has  become  one
of  the  immediate  public  health  concerns  in  China.
According  to  the  reports  of  the  International  Diabetes
Federation  (IDF)  and  American  Diabetes  Association  (ADA),
most  patients  with  type  2  diabetes  mellitus  (T2DM)  and
some  patients  with  type  1  diabetes  mellitus  are  present  with
IGT  before  the  onset  of  DM.  Currently,  several  large-scale
clinical  trials  had  been  conducted  to  determine  whether
lifestyle  or  drug  intervention  can  delay  or  reverse  the
development  and  progression  of  DM.4—6 Of  these  studies,
‘The  Da  Qing  IGT  and  Diabetes  Study’,  is  the  ﬁrst  inter-
national,  randomized  clinical  trial,  designed  to  assess  theamong  Chinese  over  age  20  were  reported  as  9.7%  and  15.5%
in  2008,2 and  were  signiﬁcantly  increased  to  11.6%  and  50.1%
in  2013.3 In  China,  approximately  148  million  people  were
diagnosed  with  IGT  indicates  impaired  glucose  regulation
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pffects  of  lifestyle  intervention  on  the  prevention  of  DM  in
atients  with  IGT.  That  study  demonstrated  the  vital  role
f  lifestyle  intervention  in  the  prevention  of  overt  DM  in
atients  with  IGT.  During  a  6-year  follow-up  study,  the  diet
8i
t
e
r
g
a
t
p
i
I
m
b
P
a
(
t
c
a
I
t
a
(
T
l
b
h
S
d
c
i
o
g
t
i
p
S
T
M
t
D
I
t
ﬁ
(
f
t
(
s
(
i
w
s
o
(
s
b
c
a
p
w
s
2
0
o
p
S
P
i
t
o
p
n
a
g
E
P
c
l
d
s
a
C
P
o
t
t
S
T
o
s
(
I
e
i
w
g
a
2
<
p
144  
ntervention  group,  the  exercise  intervention  group,  and
he  diet  combined  exercise  intervention  combined  group
xhibited  a  35%,  46%,  and  41%  reduction  in  the  incidence
ate  of  DM  respectively,  when  compared  with  the  control
roup.  Moreover,  a  43%  reduction  in  the  incidence  rate  and
 3.6-year  delay  of  the  onset  of  overt  DM  were  observed  in
he  lifestyle  intervention  group,  during  a  20-year  follow-up
eriod.7 However,  for  most  patients  staying  with  a  lifestyle
ntervention  over  a  long  period  of  time  is  very  difﬁcult.
n  addition  to  lifestyle  interventions,  treatment  with
edications,  such  as  acarbose,  metformin,  etc.,  can  also
e  used  to  prevent  or  delay  the  onset  of  IGT.  The  Diabetes
revention  Program,8,9 Finnish  Diabetes  Prevention  Study,10
nd  Study  to  Prevent  Non-Insulin-Dependent  Diabetes  trial
STOP-NIDDM)11 have  shown  that  the  above  drugs  can  reduce
he  risk  of  developing  overt  T2DM  to  varying  degrees.
In  Traditional  Chinese  Medicine  (TCM),  based  on  the
linical  symptoms,  IGT  is  categorized  as  ‘‘spleen  pyretic
bundance’’.  Traditional  Chinese  Medicine  interventions  for
GT  are  intended  to  prevent  DM.  Based  on  clinical  observa-
ions  and  TCM  experience  the  symptoms  of  IGT  are  viewed
s  spleen  deﬁciency  and  damp  overabundance  syndrome
SDDOS).
It is  well  known  that  many  active  components  used  in
CM,  including  polysaccharides,  glycosides,  ﬂavonoids,  alka-
oids  and  terpenoids,  have  a  hypoglycemic  activity.  It  has
een  suggested  that  Shenzhu  Tiaopi  granule  (SZTP)  can
elp  strengthen  the  spleen  and  remove  the  dampness.  The
ZTP  is  mainly  composed  of  codonopsis  pilosula,  rhizoma
ioscoreae,  rhizoma  atractylodis,  poria  cocos,  pericarpium
itri  reticulatae,  and  radix  glycyrrhizae  preparata.  The  dose
s  respectively  15  g,  12  g,  10  g,  10  g,  6  g,  6 g.  The  component
f  these  herbs  have  found  to  be  effective  in  lowering  blood
lucose.12—18
Here  we  report  the  results  of  a  randomized  controlled
rial  to  assess  the  efﬁcacy  of  SZTP  combined  with  lifestyle
ntervention  in  the  prevention  and  treatment  of  IGT  in
atients  with  SDDOS.
ubjects and methods
he  First  Afﬁliated  Hospital  of  Anhui  University  of  Chinese
edicine  Ethics  Committee  (Hefei,  China)  approved  the  pro-
ocols  in  this  study  (Approval  ID:  2011AH-001-04).
iagnosis  criteria
n  the  current  study,  IGT  was  deﬁned  (per  the  criteria  of
he  World  Health  Organization  for  the  diagnosis  and  classi-
cation  of  DM  [1999])  as  a  2-h  postprandial  blood  glucose
2  hPG)  ≥7.8  mmol/L  but  <11.1  mmol/L  in  the  presence  of  a
asting  plasma  glucose  (FPG)  concentration  <7.0  mmol/L.
The  TCM  standard  of  SDDOS  was  established  based  on
he  national  standard  of  the  People’s  Republic  of  China
GB/T,  l6751.2-1997)  and  the  characteristics  of  SDDOS
ymptoms.19 The  primary  symptoms  included  the  following:
1)  fatigue;  (2)  heavy  sensation  in  the  body  and  fullness
n  the  epigastria  and  abdomen,  and  (3)  stickiness  but
ithout  desire  to  drink,  or  thirst  with  desire  to  drink.  The
econdary  symptoms  were  as  follows:  (1)  overweight  or
besity;  (2)  shortness  of  breath  and  disinclination  to  talk;
d
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3)  blood  stagnation,  nausea  and  vomiting;  (4)  spontaneous
weating  or  sweating  during  the  night;  (5)  viscous,  loose
owels  or  constipation;  (6)  pale  tongue  with  white  or  greasy
oating,  accompanied  with  indentation;  and  (7)  relaxed
nd  soft  pulse.  Patients  exhibiting  at  least  two  of  the
rimary  symptoms  and  three  of  the  secondary  symptoms
ere  diagnosed  as  having  SDDOS.  The  standard  of  TCM
ymptomatic  scores  is:  (1)  primary  symptoms:  0  =  none,
 =  slight,  4  =  moderate,  6  =  severe;  (2)  secondary  symptoms:
 =  none,  1  =  slight,  2  =  moderate,  3  =  severe;  (3)  condition
f  tongue:  0  =  absence,  1  =  presence;  and  (4)  condition  of
ulse:  0  =  absence,  1  =  presence.
election  criteria
atients  were  screened  according  to  the  criteria  of:  meet-
ng  both  the  western  medical  diagnostic  criteria  for  IGT  and
he  TCM  diagnostic  criteria  for  SDDOS;  conﬁrmed  diagnosis
f  IGT  in  suspicious  cases,  followed  by  one-month  washout
eriod;  male  or  female  between  the  ages  of  25  and  70;  had
ot  been  treated  for  IGT  previously;  had  not  participated  in
ny  other  clinical  trials  during  the  last  three  months;  and
ave  voluntary  informed  consent.
xclusion  criteria
atients  were  excluded  if  they  had:  acute  cardio-
erebrovascular  events  during  the  last  six  months;  severe
iver  or  kidney  dysfunction;  malignancy;  psychiatric  disor-
ers;  and  with  complications  of  other  endocrine  diseases;
erious  primary  diseases.  Pregnant  or  lactating  women  were
lso  excluded.
riteria  for  withdrawing  patients  from  the  study
atient  were  withdrawn  from  the  study  if  they:  were  unable
r  unwilling  to  adhere  to  study  protocols,  dropped  out  of
he  study,  or  suffered  a  severe  adverse  event  that  prevented
hem  for  adhering  to  study  protocols  e.g.  heart  attack.
ample  size  and  statistical  analysis
he  incidence  rate  of  patients  with  IGT  who  converted  to
vert  DM  was  the  primary  endpoint  of  the  study.  The  sample
ize  was  calculated  using  Statistic  Package  for  Social  Science
SPSS)  version  17.0  statistical  software  (version  17.0,  SPSS
nc,  Chicago,  IL,  USA)  with  an  equal  number  of  patients  in
ach  group  (two-tailed  test,  power  =  0.80,  ˛  = 0.05).  Accord-
ng  to  the  previous  reports,  the  incidence  rates  of  patients
ith  IGT  who  converted  to  overt  DM  in  the  control  and  test
roups  were  assumed  to  be  46.0%  and  32.8%,  respectively,7,11
nd  the  required  sample  sizes  were  then  estimated  to  be
14  patients  in  each  group.  The  expected  dropout  rate  was
20%,  the  study  investigators  therefore  decided  to  enroll  514
atients.
Statistical  analyses  were  performed  using  SPSS  version
7.0  statistical  software.  Normally  distributed  measurement
ata  were  expressed  as  means  and  standard  devia-
ions  (mean  ±  standard  deviation  SD).  The  effective  rates
etween  groups  were  compared  with  the  Chi-square  test.
he  differences  before  and  after  treatment  were  compared
rvention  on  impaired  glucose  tolerance  845
Assessed for eligibility (n=617)
Excluded (n=103)
Did not meet inclusion criteria (n=91)
Declined to  participate  (n=12)
Randomized (n=514)
All oca ted  to  the con trol  group
(n=257)
Allocated to the experimental
group (n=257)
Lost to  follow-up (n=41) Lost to follow-up (n =34)
Analyzed (n=216) Analyzed (n=223)
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by  paired  t-test.  The  ranked  data  were  compared  using  the
Ridit  test.  P  <  0.05  was  considered  to  be  statistically  signiﬁ-
cant.
Treatment  regimen
After  one-month  washout  period,  enrolled  patients  were
randomized  to  the  control  or  experimental  groups,  in  a
1:1  ratio.  Patients  in  the  control  group  received  a  lifestyle
intervention  for  12  months,  based  on  the  Chinese  guidelines
prevention  and  treatment  of  T2DM20 and  dietary  advice  for
treatment  of  T2DM  in  adults.21 These  patients  were  encour-
aged  to  consume  more  vegetables,  control  their  intake  of
alcohol,  and  reduce  their  intake  of  simple  sugars.  Mean-
while,  they  were  taught  and  encouraged  to  increase  the
amount  of  their  leisure  physical  exercise  by  at  least  once
a  day.  The  patients  in  the  experimental  group  received
8.8  g of  oral  SZTP  (offered  by  the  Pharmaceutical  For-
mulations  Center  of  the  First  Afﬁliated  Hospital  of  Anhui
University  of  Traditional  Chinese  Medicine,  Anhui,  China
[Lot,  BZ20080027])  twice  daily  plus  lifestyle  intervention  for
12  months.  All  the  investigators  were  trained  and  certiﬁed
before  the  study.
Variables  assessed
The  variables  assessed  included  general  demographic  infor-
mation,  as  well  as  the  levels  of  FPG,  2  hPG,  glycosylated
hemoglobin  A1c  (HbA1c),  triglycerides  (TG),  total  choles-
terol  (TC),  high  density  lipoprotein  cholesterol  (HDL-C),
and  low  density  lipoprotein  cholesterol  (LDL-C)  in  both  the
groups.  The  levels  of  FPG,  2  hPG  and  HbA1c  was  assessed
every  three  months,  whereas  the  other  variables  were
measured  before  and  after  the  treatment.  The  symptoms
according  to  the  TCM;  conditions  of  tongue  and  pulse  were
also  recorded  for  all  patients.
Patient  safety  variables  included  physical  examination,
routine  blood  and  urine  tests,  liver  and  kidney  functions,
and  electrocardiogram  (ECG)  measurements.
Evaluation  of  efﬁcacy
Evaluation  of  treatment  efﬁcacy.  The  primary  clinical  efﬁ-
cacy  of  the  two  treatments  was  evaluated  by  changes  in  the
laboratory  examination  of  IGT  before  and  after  treatment
in  both  the  groups.22,23 There  were  three  assessment  levels,
including:  signiﬁcant  impact,  modest  impact  and  no  impact,
which  were  deﬁned  as  follows:  signiﬁcant  impact:  an  FPG
<7.0  mmol/L  and  a  2  hPG  <7.8  mmol/L  after  treatment;  mod-
est  impact:  an  FPG  <7.0  mmol/L  and  a  2  hPG  ≥7.8  mmol/L
but  <11.1  mmol/L  after  treatment;  and  no  impact:  an  FPG
≥7.0  mmol/L  or  a  2  hPG  ≥11.1  mmol/L  after  treatment.
The  change  in  a  single  TCM  symptom  was  considered  as
secondary  variables  (for  the  efﬁcacy  of  TCM),  which  were
classiﬁed  as:  (1)  signiﬁcant  impact:  original  symptoms  disap-
peared  or  were  improved  by  two  grades;  (2)  modest  impact:
original  symptoms  were  improved  by  one  grade  but  did  not
disappear;  and  (3)  no  impact:  there  were  no  changes  in
original  symptoms.
Another  secondary  efﬁcacy  evaluation  of  TCM  symptoms
was  deﬁned  as  follows:  (1)  high  impact:  TCM  symptoms  com-
pletely  or  largely  disappeared,  and  the  TCM  symptomatic
scores  decreased  by  ≥90%;  (2)  modest  impact:  clinical
symptoms  were  obviously  improved  with  symptomatic
w
t
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tigure  1  The  consort  ﬂow  diagram  of  the  randomized  con-
rolled  trial.
cores  decreased  by  ≥70%  but  less  than  <90%;  (3)  minor
mpact:  clinical  symptoms  were  improved  to  some  extent,
ith  symptomatic  scores  decreased  by  ≥30%  but  less  than
70%;  and  (4)  no  impact:  clinical  symptoms  were  not
bviously  improved  or  even  aggravated,  with  symptomatic
cores  decreased  by  <30%.
esults
rocedure  and  subjects
fter  signing  informed  consent,  patients  at  high  risk  of
M  were  screened  by  ﬁnger-prick  blood  glucose  level  mea-
urements  by  glucometer  (ONE  TOUCH-ULTRA,  Johnson  and
ohnson,  Co,  USA)  at  four  community  health  service  cen-
ers  in  Hefei,  Anhui,  China,  resulting  in  the  identiﬁcation
f  1814  suspicious  cases  of  IGT  all  told.  All  of  these  suspi-
ious  IGT  patients  underwent  an  oral  glucose  tolerance  test
OGTT)  with  75  g  glucose  on  the  next  day  at  the  Experiment
enter  of  the  First  Afﬁliated  Hospital  of  Anhui  University  of
hinese  Medicine,  Anhui,  China,  and  1496  cases  were  diag-
osed  by  oxidase  assay  in  2—3  ml  venous  blood  collection.
here  were  617  patients  who  had  SDDOS,  There  were  879
atients  with  other  syndromes.  For  example  Qi  and  Yin  deﬁ-
iency  syndrome,  blood  stasis  syndrome,  deﬁciency  of  both
in  and  Yang  syndrome.  TCM  syndrome  type  is  diagnosed
y  professor  of  medicine.  The  same  professor  of  medicine
xamined  the  patients  at  the  beginning  and  at  the  end  of
he  study.  With  the  OGTT  test  after  a  one-month  washout
eriod  a  total  of  514  patients  were  diagnosed  with  SDDOS
GT  (Fig.  1).  Patients  were  re-examined  each  month  by  a
ommunity  doctor  according  the  study  protocol  to  assess
he  indexes  described  in  the  ‘‘Variables  assessed’’  section.
he  community  followed-up  with  the  study  participants  each
eek  by  telephone  or  by  a  home  visit  to  monitor  and  record
he  conditions  their  degree  of  compliance  with  the  lifestyle
ntervention  and  medication  regimen.  The  community  doc-
or  also  discussed  and  helped  resolve  problems  patients
846  Z.  Fang  et  al.
Table  1  Comparison  of  baseline  demographic  characteristics  in  the  two  groups.
Variable  Lifestyle  intervention
group  (n  =  257)
SZTP  plus  lifestyle
intervention  group
(n =  257)
T  value  P  value
Male:female  142:115  136:121  0.282  0.595
Age (mean  ±  SD,  year)  54.61  ±  10.51  54.95  ±  9.50  −0.378  0.705
Disease duration  (mean  ±  SD,  month)  5.08  ±  10.56  3.73  ±  7.22  1.681  0.093
Height (mean  ±  SD,  cm)  163.05  ±  8.18  163.43  ±  8.29  −0.638  0.524
Body weight  (mean  ±  SD,  kg)  67.53  ±  11.02  67.67  ±  10.77  −0.173  0.863
BMI (mean  ±  SD,  kg/m2) 25.33  ±  3.21  25.27  ±  3.14  0.272  0.786
Wc (mean  ±  SD,  cm) 90.71  ±  8.15 89.69  ±  8.83 1.260 0.208
Hc (mean  ±  SD,  cm) 97.96  ±  6.81 97.18  ±  7.58 1.223 0.222
FPG (mean  ±  SD,  mmol/l) 5.70  ±  0.55 5.71  ±  0.52 −0.019 0.985
2 hPG  (mean  ±  SD,  mmol/l)  9.23  ±  0.81  9.30  ±  0.95  −0.910  0.363
HbA1c (mean  ±  SD,  %)  6.06  ±  0.55  6.13  ±  0.60  −1.460  0.145
TG (mean  ±  SD,  mmol/L)  1.59  ±  0.72  1.58  ±  0.78  0.062  0.950
TC (mean  ±  SD,  mmol/L)  5.28  ±  1.14  5.30  ±  1.16  −0.098  0.922
HDL-C (mean  ±  SD,  mmol/L)  1.38  ±  0.54  1.45  ±  0.65  −1.088  0.277
LDL-C (mean  ±  SD,  mmol/L)  2.44  ±  0.53  2.47  ±  0.94  −0.389  0.697
SBP (mean  ±  SD,  mmHg)  131.79  ±  16.16  130.62  ±  15.57  1.023  0.307
DBP (mean  ±  SD,  mmHg)  84.24  ±  6.70  84.29  ±  7.40  −0.080  0.936
Family history  of  hypertension  [n  (%)]  65  (25.29)  61  (23.73)  0.168  0.758
Family history  of  diabetes  mellitus  [n  (%)]  30  (11.67)  33  (12.84)  0.163  0.788
History of  smoking  [n  (%)]  130  (50.58)  125  (48.63)  0.195  0.724
History of  drinking  [n  (%)]  158  (61.47)  161  (62.64)  0.074  0.856
SZTP, ShenZhu TiaoPi granule; BMI, body mass index; Hc, hip circumference; Wc, waist and hip circumference; FPG, fasting blood
glucose; 2 hPG, 2-h postprandial blood glucose; HbA1c, glycosylated hemoglobin; TG, triglyceride; TC, total cholesterol; HDL-C, high
density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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Cere  having  complying  with  the  study  protocol  of  the  group
o  which  they  were  assigned.  These  weekly  visits  ensured  a
igh  degree  of  compliance  with  the  study  protocols.
omparison  of  baseline  characteristics
t  the  end  of  the  clinical  trial,  439  out  of  514  patients  had
ompleted  the  study.  A  total  of  75  patients  were  lost  to
ollow-up  during  the  12  months  of  the  study,  which  included
1  in  the  control  group  and  34  in  the  experimental  group;  no
igniﬁcant  differences  were  observed  in  the  drop  out  rates
etween  the  two  groups  (15.95%  vs.  13.23%;  P  >  0.05).  Five
atients  were  dissatisﬁed  with  the  treatment  process,  11
atients  failed  to  complete  the  course  of  follow-up  appoint-
ents,  and  27  patients  decided  that  it  would  take  a  long
ime  before  the  onset  of  DM  and  did  not  wish  to  continue
ith  treatment  for  their  IGT,  18  of  the  patients  worked  and
ere  unable  to  make  time  for  the  study,  14  patients  noted
dverse  events.  Thus,  the  analysis  included  216  patients  in
he  control  group  and  223  patients  in  the  experimental  group
Fig.  1).  There  were  no  signiﬁcant  differences  between  the
wo  groups  in  their  baseline  characteristics  including  age,
ex  ratio,  disease  duration,  height,  body  weight,  body  mass
ndex  (BMI),  hip  circumference  (Hc),  waist  circumference
Wc),  FPG,  2  hPG,  HbA1c,  TG,  TC,  HDL-C,  LDL-C,  systolic
lood  pressure  (SBP),  and  diastolic  blood  pressure  (DBP)
Table  1).
A
H
tomparison  of  baseline  clinical  symptoms
t  study  entry,  obesity  and  fatigue  were  the  symptoms
eported  most  frequently.  In  all  514  patients  assessed  299
58.17%)  were  obese  and  281  (54.67%)  patients,  reported
eeling  fatigued.  The  most  common  symptoms  of  SDDOS
t  baseline  were  stickiness  but  without  desire  to  drink
49.03%),  thirsty  with  desire  to  drink  (41.83%),  and  fullness
n  the  epigastria  of  abdomen,  (41.25%).  Shortness  of  breath
nd  disinclination  was  only  noted  in  112  patients  (21.79%)
Table  2).
omparisons  of  conversion  rate
ollowing  12  months  of  treatment,  the  conversion  rate  of
GT  to  DM  in  the  experimental  group  was  signiﬁcantly  lower
han  that  in  the  control  group  (15.28%  vs.  8.52%,  P  <  0.05).
he  rate  of  conversion  from  IGT  to  normal  blood  glucose
olerance  was  signiﬁcantly  higher  in  the  experimental  group
s  compared  to  that  in  the  control  group  (42.15%  vs.  32.87%,
 <  0.05)  (Table  3).
omparisons  of  levels  of  FPG,  2  hPG  and  HbA1cfter  12  months  of  treatment,  the  levels  of  2  hPG  and
bA1c  were  reduced  in  both  the  experimental  and  con-
rol  group  compared  with  those  scores  at  baseline.  However
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Table  2  Comparison  of  clinical  symptoms  in  the  two  groups  [n  (%)].
Symptom,  n  (%)  Lifestyle  intervention
group  (n  =  257)
SZTP  plus  lifestyle  intervention  group
(n =  257)  Formatting  problem
Total  n  (%)
Fatigue  137  (53.31%)  144  (56.03%)  281  (54.67%)
Heavy sensation  in  the
body
119  (46.30%) 88  (53.31%) 207  (40.27%)
Fullness in  the  epigastria
and  abdomen
103  (40.08%)  109  (53.31%)  212  (41.25%)
Stickiness but  without
desire  to  drink
126  (49.03%)  126  (53.31%)  252  (49.03%)
Thirsty with  desire  to
drink
105  (40.86%)  110  (53.31%)  215  (41.83%)
Obesity 146  (56.80%) 153  (53.31%)  299  (59.53%)
Shortness of  breath  and
disinclination  to  talk
53  (20.62%)  59  (53.31%)  112  (21.79%)
Stagnancy 95  (36.96%)  96  (53.31%)  191  (37.16%)
Spontaneous sweating  61  (23.74%)  54  (53.31%)  115  (22.37%)
Loose bowels  95  (36.96%)  105  (53.31%)  200  (38.91%)
Constipation 89  (34.63%)  72  (53.31%)  161  (31.32%)
Symptom scores  9.61  ±  2.57  9.66  ±  2.33
SZTP, ShenZhu TiaoPi granule.
Table  3  Comparison  of  conversion  rate  of  IGT  to  DM  or  normal  blood  glucose  tolerance  in  the  two  groups.
Group  n  (%)  2 P  value
Lifestyle  intervention  group  (n  =  216)  33  (15.28%)  4.798  0.028
SZTP plus  lifestyle  intervention  group  (n  =  223)  19  (8.52%)*
Lifestyle  intervention  group  (n  =  216)  71  (32.87%)  4.030  0.045
SZTP plus  lifestyle  intervention  group  (n  =  223)  94  (42.15%)*
w
c
i
t
t
a
ISZTP, ShenZhu TiaoPi granule.
* P < 0.05 vs. the control group after 12 months of treatment.
those  before  and  after  treatment  differences  were  not  stat-
ically  signiﬁcant  (P  >  0.05).  However,  the  2  hPG  before  levels
and  after  levels  differences  the  levels  in  the  experimental
group  were  signiﬁcantly  lower  compared  those  in  the  control
group.  (P  < 0.01)  (Table  4).
Comparisons  of  cardiovascular  risk  factors  and
serum lipid  levels
After  12  months  of  treatment,  the  baseline  values  of  car-
diovascular  risk  factors  such  as  body  weight,  BMI  and  Wc
c
t
b
i
Table  4  Comparison  of  levels  of  blood  sugar  after  treatment  in  t
Index  Lifestyle  intervention  group  
Before  treatment
(n =  257)
After  treatme
(n  =  216)
FPG  (mmol/l)  5.70  ±  0.81  5.60  ±  0.77  
2 hPG  (mmol/l)  9.23  ±  0.81  8.88  ±  1.92  
HbA1c  (%)  6.06  ±  0.55  5.84  ±  0.59  
SZTP, ShenZhu TiaoPi granule.
** P < 0.01 vs. the control group after 12 months of treatment.ere  reduced  numerically  more  in  the  experimental  group
ompared  to  the  control  group.  However,  there  were  no  stat-
cally  signiﬁcant  differences  in  all  the  above  factors  between
he  two  groups  (P  >  0.05).  Furthermore,  after  12  months  of
reatment,  change  from  baseline  in  the  levels  of  Hc,  SBP
nd  DBP  in  both  the  groups  were  not  signiﬁcant  (P  >  0.05).
n  the  experimental  group,  the  TG  levels  were  numeri-
ally  reduced  in  comparison  with  that  at  baseline,  whereas
here  were  no  statistically  signiﬁcant  differences  observed
etween  the  two  groups  (P  >  0.05).  In  addition,  in  the  exper-
mental  group,  there  were  no  discernable  changes  in  the
he  two  groups  (mean  ±  SD).
SZTP  plus  lifestyle  intervention  group
nt Before  treatment
(n =  257)
After  treatment
(n  =  223)
5.71  ±  0.90  5.52  ±  0.82
9.30  ±  0.95  8.35  ±  1.54**
6.13  ±  0.60  5.73  ±  0.66
848  Z.  Fang  et  al.
Table  5  Comparison  of  baseline  after  treatment  in  the  two  groups  (mean  ±  SD).
Index  Lifestyle  intervention  group  SZTP  plus  lifestyle  intervention  group
Before  treatment
(n =  257)
After  treatment
(n  =  216)
Before  treatment
(n =  257)
After  treatment
(n  =  223)
Body  weight  (kg)  67.53  ±  11.02  67.02  ±  9.68  67.67  ±  10.77  66.81  ±  10.22
BMI (kg/m2)  25.33  ±  3.21  24.97  ±  2.86  25.27  ±  3.14  24.76  ±  2.72
Wc (cm)  90.71  ±  8.15  90.35  ±  7.77  89.69  ±  8.83  88.97  ±  8.12
Hc (cm)  97.96  ±  6.81  97.86  ±  6.68  97.18  ±  7.58  96.97  ±  7.17
SBP (mmHg)  131.79  ±  16.16  131.03  ±  16.87  130.62  ±  15.57  129.79  ±  15.20
DBP (mmHg)  84.24  ±  6.70  83.88  ±  6.99  84.29  ±  7.40  83.84  ±  7.20
TC (mmol/L) 5.28  ±  1.14 5.24  ±  1.11 5.30  ±  1.16  5.24  ±  1.13
TG (mmol/L) 1.59  ±  0.72 1.56  ±  0.69 1.58  ±  0.78 1.49  ±  0.75
HDL-C (mmol/L)  1.38  ±  0.54  1.45  ±  0.70  1.45  ±  0.65  1.90  ±  0.51
LDL-C (mmol/L)  2.44  ±  0.53  2.40  ±  0.56  2.47  ±  0.94  2.42  ±  0.86
SZTP, ShenZhu TiaoPi granule; BMI, body mass index; Hc, hip circumference; Wc, waist and hip circumference; SBP, systolic blood
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evels  of  TC,  HDL-C  and  LDL-C  before  and  after  treatment
Table  5).
omparisons  of  efﬁcacy  and  scores  on  single  TCM
ymptom
fter  12  months  of  treatment,  the  symptoms  of  ‘fatigue
nd  stickiness  but  without  desire  to  drink’  were  signiﬁ-
antly  more  improved  in  the  experimental  group  compared
ith  the  control  group  (P  <  0.01).  Moreover,  there  was  a
igniﬁcant  improvement  in  the  symptoms  including  ‘heavy
ensation  in  the  body,  fullness  in  the  epigastria  and
bdomen,  obesity,  as  well  as  loose  bowels’  (P  <  0.05).  The
otal  efﬁcacy  rate  in  the  experimental  group  was  superior
o  that  in  the  control  group  after  12  months  of  treatment
86.78%  vs.  81.48%),  with  signiﬁcant  difference  (  =  3.131,
 <  0.05).  At  baseline,  there  were  no  signiﬁcant  differences
n  terms  of  the  TCM  symptomatic  scores  between  the  two
reatment  groups  (P  >  0.05).  After  12  months  of  treatment,
he  TCM  symptomatic  scores  in  the  control  and  experimen-
al  groups  were  4.81  ±  2.23  and  3.55  ±  1.86,  respectively,
hich  decreased  signiﬁcantly  (P  <  0.01)  compared  to  the
aseline  values.  Furthermore,  the  scores  above  improved
igniﬁcantly  (P  <  0.05)  in  the  experimental  group  as  com-
ared  to  the  control  group  after  treatment  (Table  6).
omparisons  of  safety  evaluation  and  adverse
vents
ollowing  the  treatment  for  12  months,  AEs  were  noted  in  14
atients,  including  ﬁve  in  the  control  group  and  nine  in  the
xperimental  group.  Of  which,  13  patients  experienced  gas-
rointestinal  reactions,  and  one  patient  had  pruritus.  There
ere  no  signiﬁcant  (P  >  0.05)  differences  in  the  incidence
f  AEs  between  the  two  groups.  All  reported  AEs  were  mild
oderate  in  severity;  no  serious  AEs  were  reported.  Eight
atients  were  withdrawn  from  the  study  due  to  these  AEs.
m
i
t
tlesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low
iscussion
GT  has  been  considered  as  an  intermediate  metabolic
tate  between  normal  blood  glucose  levels  and  DM,  and
 transient  stage  in  the  development  of  DM  from  normal
lucose  tolerance.  IGT  is  characterized  by  an  increase  in  the
ostprandial  glucose  levels.  The  reduction  in  second-phase
nsulin  secretion  and  peripheral  insulin  resistance  (IR)  in
keletal  muscle  provide  a common  mechanism  for  the
athogenesis  of  IGT;  IGT  is  reported  to  be  closely  related
o  the  function  of  pancreas.
In  the  present  study,  the  male  patients  were  1.18  times
igher  in  number  than  those  of  the  female  patients  (54.09%
s.  45.91%),  indicating  that  the  prevalence  of  IGT  was  higher
n  males,  which  could  be  viewed  as  a  consequence  of  their
rregular  lifestyle  and  higher  levels  of  work  pressure.3,24
he  living  habits  of  males  maybe  affect  their  health,  for
xample,  smoking,  consumption  of  alcohol  drinking,  lack  of
xercise,  and  poor  dietary  habits.3,24
There  were:  51  patients  aged  ≤40  years  (9.92%);  116
atients  aged  41—50  (22.57%),  168  patients  aged  51—60
32.68%)and  178  patients  aged  61—70  (34.63%).  The  study
omprised  346  (67.31%)  patients  with  in  the  age  range  of
1—70  years  were  at  particularly  high  risk  for  IGT  conﬁrming
he  results  of  a  previous  study  conducted  in  China  that
howed  IGT  is  age  dependent.25
In  all  514  patients  with  IGT,  a  total  of  126  (24.51%)
atients  had  a  family  history  of  hypertension.  This  indi-
ates  that  periodic  follow-up  should  be  conducted  for  those
atients  in  order  to  prevent  more  severe  morbidity  caused
y  hypertension.  Consistent  with  the  results  obtained  from
he  previous  studies,  the  most  common  clinical  symptom
eported  in  the  enrolled  patients  was  obesity  (59.53%).
The  results  of  this  study  show  that  compared  with  the
ifestyle  intervention  alone,  lifestyle  intervention  combined
ith  TCM  therapy  was  more  effective  in  reversing  IGT  to  nor-
al  glucose  tolerance  there  by  reducing  the  onset  of  DM.  It
s  also  suggested  that  the  DM  was  unlikely  to  be  well  con-
rolled  with  lifestyle  interventions  alone  because  of  the  of
he  difﬁculty  patients  suffering  from  obesity,  IGT  or  type  2
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Table  6  Comparison  of  efﬁcacy  on  single  TCM  symptom  before  and  after  treatment  in  the  two  groups.
Symptom  Lifestyle  intervention  group  (n  =  216)  SZTP  plus  lifestyle  intervention  group  (n  =  223)
n  Excellence  Effect  Invalid  Efﬁcacy  rate
(%)
n  Excellence  Effect  Invalid  Efﬁcacy  rate
(%)
Fatigue  115  41  49  25  78.26  120  61  45  14  88.33**
Heavy  sensation  in
the  body
96  35  37  24  75.00  82  41  30  11  86.58*
Fullness  in  the
epigastria  and
abdomen
92  34  36  22  76.08  99  48  38  13  86.86*
Stickiness  but  without
desire  to  drink
97  41  31  25  74.22  111  61  34  12  88.78**
Thirst  with  desire  to
drink
93  37  30  26  72.04  92  41  33  18  80.43
Obesity 113  56  31  26  76.99  110  69  27  14  87.27*
Shortness  of  breath
and  disinclination
to  talk
44  20  11  13  70.45  46  30  7  9  80.43
Stagnancy  85  39  27  19  77.64  84  49  25  10  88.09
Spontaneous  sweating  46  17  19  10  78.26  49  26  15  8  83.67
Loose bowels  72  29  30  13  81.94  91  49  34  8  91.20*
Constipation  84  33  32  19  77.38  64  30  24  10  84.37
Curative effect  216  100  68  48  77.32%  223  123  84  16  86.78%**
Scores  4.81  ±  2.23 3.55  ±  1.86*,
SZTP, ShenZhu TiaoPi granule.
* P < 0.05 vs. the control group after 12 months of treatment.
** P < 0.01 vs. the control group after 12 months of treatment.
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diabetes  have  in  losing  weight  and/or  increasing  their  level
of  physical  activity.  These  observations  support  the  need  to
develop  a  comprehensive  plan  with  multiple  strategies  to
prevent  and  treat  DM.  The  patients  whose  blood  glucose  lev-
els  returned  to  normal  are  still  at  higher  risk  of  developing
IGT  and/or  overt  type  2  diabetes.  Therefore  in  addition  to
long-term  follow-up  and  assessment  these  patients  should
be  provided  with  further  health  education.  This  would  help
in  evaluating  the  long-term  efﬁcacy  of  TCM  in  combination
with  western  medicine  in  the  treatment  of  patients  with  IGT
and  it  would  provide  the  foundation  for  the  development
further  feasible  and  effective  strategies  for  the  preventing
and  treating  of  IGT.
There  were  no  signiﬁcant  differences  in  incidence  of
adverse  events  (P  >  0.05)  between  the  two  groups.  None
of  the  patients  reported  any  serious  adverse  events  (SAE).
Following  the  12-month  treatment  period,  there  were  no
noticeable  changes  in  the  related  indices  of  routine  blood
and  urine  tests,  kidney  function  tests  and  ECG  in  both  the
groups,  suggesting  the  tolerability  of  these  treatment  regi-
mens  in  the  selected  population  is  high.  In  addition,  there
were  no  signiﬁcant  differences  regarding  the  dropout  rate
between  the  experimental  group  and  control  groups  (15.95%
vs.  13.23%,  P  > 0.05).
However,  there  are  some  limitations  of  the  current  study.
The  duration  of  follow-up  was  not  enough  to  assess  the  long-
term  efﬁcacy  of  the  experimental  approach,  which  warrants
further  follow-up  studies  to  verify  the  efﬁcacy  of  the  exper-
imental  approach.  Based  on  the  available  data,  we  plan  tourther  our  understanding  TCM  and  western  medicine  in  rela-
ion  to  IGT,  in  order  to  develop  more  innovative  approaches
n  using  TCM  prevent  and  treat  of  IGT.  Meanwhile,  consen-
us  from  the  experts  about  efﬁcacy  of  the  approach  used
n  the  experimental  group  can  help  us  optimize  our  current
reatment  regimens.  We  also  hope  to  achieve  more  repre-
entative  results  through  a  national  study,  which  would  be
reatly  beneﬁcial  in  the  using  TCM  to  prevent  and  treat  IGT.
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